NexGel, Inc.
NXGL Healthcare Medical Instruments & Supplies
NexGel, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.4 million, up 31.5% from fiscal 2024. In the quarter to June 2026, revenue grew 27.8%, EPS fell 344.4%, free cash flow fell 432.3% and total debt rose 353.8%, each against the same quarter a year earlier. Dividend growth for three consecutive years, revenue growth for five.
Follow NXGL
NexGel, Inc. (NXGL) EV/Sales
As of 16 October 2026, NexGel, Inc. (NXGL) trades at a EV/Sales of 4.3×. Over the past ten years it has ranged from 2.4× (October 2026) to 186× (December 2021); the current reading is higher than 2% of that period. That is above the Medical Instruments & Supplies industry median of 2.9× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 22.1× | (66.86%) |
| FY2024 | 66.8× | 7.88% |
| FY2023 | 61.9× | (12.10%) |
| FY2022 | 70.4× | (23.36%) |
| FY2021 | 91.9× | (50.71%) |
| FY2020 | 186× | 0.00% |
| FY2019 | 186× | 0.00% |
| FY2018 | 186× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 7.7× | (16.94%) |
| Mar 2026 | 9.2× | (58.34%) |
| Dec 2025 | 22.1× | (33.48%) |
| Sep 2025 | 33.3× | (1.76%) |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RVP Retractable Technologies, Inc. compare | −0.6× |
| RGNT Regentis Biomaterials Ltd. compare | n/m |
| CUPR Cuprina Holdings (Cayman) Limited compare | n/m |
| LUCY Innovative Eyewear, Inc. compare | 0.4× |
| BNGO Bionano Genomics, Inc. compare | 0.7× |
| HBIO Harvard Bioscience, Inc. compare | 1.1× |
| MLSS Milestone Scientific, Inc. compare | 3.1× |
| FEMY Femasys Inc. compare | 3.4× |
| NXGL NexGel, Inc. | 4.3× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)